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Abstract
A subset of CD4+ T cells, the CD4+ CD25+ Treg cells in the lymphoid organs and peripheral blood
are known to possess suppressive function. Previous in vitro and in vivo studies have indicated that
T cell receptor (TCR) signal is required for development of such ‘natural regulatory (Treg) cells’ and
for activation of the effector function of CD4+ CD25+ regulatory T cells. CD5 is a cell surface
molecule present on all T cells and a subtype of B lymphocytes, the B-1 cells, primarily localized to
coelomic cavities, Peyer’s patches, tonsils and spleen. CD5 acts as a negative regulator of T cell and
B cell signaling via recruitment of SHP-1. Here, we demonstrate that Treg cells obtained from
CD5−/− mice are more potent than those from wild type mice in suppressing the in vitro cell
proliferation of anti-CD3 stimulated CD4+ CD25− responder T cells. This phenomenon was cell
contact and GITR dependent. Lack of CD5 expression on Treg cells (from spleen, lymph node and
thymus) did not affect the intracellular levels of Foxp3. However, CD5−/− Treg thymocytes were able
to elicit a higher Ca2+ response to TCR + co-stimulatory signals than the wild type cells. CD5−/−
mice expressed more Foxp3 mRNA in the colon than wild type mice, and additionally, the severity
of the DSS-induced colitis in CD5−/− mice was less than the wild type strain. We suggest that
manipulation of CD5 expression or the downstream signaling components of CD4+ CD25+ Treg cells
as a potential strategy for therapeutic intervention in cases of auto-immune disorders.
Keywords
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Introduction
The recently described CD4+CD25 + regulatory T (Treg) cells are critical for peripheral
tolerance. They potently suppress the function of effector T cells. The dominant form of
peripheral tolerance induction by the CD4+ CD25+ Treg cells has been implicated to have great
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clinical relevance in both systemic and organ specific autoimmune diseases as well as
infectious diseases (1,2). The precise mechanism (s) of the Treg mediated suppression of naïve
or effector T cells in the secondary lymphoid organs and other sites of active inflammation has
not been deciphered completely (3). It is thought that the Treg cells block IL-2 production and
cause G1 arrest in the effector T cell population in a cell contact dependent manner (4). This
phenomenon of inhibition of cell proliferation has been proven to be reversible both in vitro
and in vivo (5–7). A recent study found that Treg cells induce apoptosis of the responder T cells
and that the apoptosis can be reversed by cytokines that signal through the common gamma
chain containing receptors (8). There is no absolute cell surface marker to isolate these
regulatory T cell populations in the animal models. However, CD4, CD25, CTLA-4,
Glucocorticoid-induced TNF receptor (GITR/TNFRSF18), 4-1BB, OX-40, CD103, CD38,
Neuropilin-1 (Nrp-1) are some of the cell surface proteins thought to be expressed on the
Treg cells (9,10). Foxp3 is a member of the forkhead box transcription factor family that is
exclusively expressed in the Treg cells constitutively and confers the regulatory behavior of
these cells (11–14). Overexpression studies and mutant mice have confirmed that Foxp3 is
required for the generation and maintenance of Treg cells but its precise role in T-reg function
is still being elucidated (12,15).
The suppressive effect of Treg cells can be overcome by supplying IL-2 in excess of
physiological levels or by blocking with an anti-GITR antibody. In vivo, neutralizing antibodies
to TGF-β and/or IL-10 can also abrogate Treg mediated suppression (16–18). Such therapies
to down modulate Treg function were effective in enhancing effector T cell function in cases
of tumor immunity and to curb infections (19,20). Attempts to induce Treg cell proliferation
with heat-shock proteins (HSP) in models of experimental autoimmunity indicate potential
therapeutic approaches since such HSP-activated T cells displayed a Treg cell-like phenotype
(21). This strategy will prove to be useful in autoimmune conditions wherein it is beneficial to
the host if Treg cells can more actively inhibit the functioning of autoreactive T cells. Moreover,
administration of dexamethasone, an immunosuppressive glucocorticoid, into wild type
BALB/c mice led to less CD4+ CD25+ T cell death compared to the CD4+ CD25− T cell
apoptosis (22). In this context, we show here that CD5, a cell surface receptor expressed on T
cells is influential in regulating the suppressive nature of Treg cells in an in vitro cell co-culture
system.
CD5 is a 67 kDa membrane glycoprotein that is expressed on all T cells and a small subset of
B cells, the B-1 type of B lymphocytes; CD5 acts as a negative regulator of T cell receptor
signaling in thymocytes and of B cell receptor signaling in B-1 cells (23,24). This occurs via
recruitment of a protein tyrosine phosphatase, SHP-1, to the cytoplasmic ITIM (immuno-
tyrosine receptor based inhibitor motif) domain of CD5 upon TCR activation (25). Thus,
thymocytes obtained from CD5−/− mice are hyper-responsive to antigen receptor signaling
(24). Introduction of transgenic CD5 into CD5−/− mice but not that encoding a truncated form
of CD5 protein was able to rescue the CD5−/− phenotype demonstrating the absolute
requirement of the cytoplasmic tail of CD5 for its inhibitory function of TCR signaling in
thymocytes (26). CD5 has also been shown to have a role in T cell anergy induced by chronic
antigen exposure (27). More recently, in a model of T cell tolerance induced by antigen targeted
to dendritic cells, the T cell unresponsiveness was linked to increased CD5 expression (28).
Since CD5 is present on all T cells, we hypothesized that it is present even on the CD4+
CD25+ regulatory T cells and, therefore, has a role in the functioning of these cells. In an in
vitro model of Treg cell function, we demonstrate that Treg cells are more effective in
suppression when they are obtained from CD5−/− mice. It has also been known that Treg cells
are activated in an antigen specific manner but the effector function of these cells is antigen
non-specific (29,30). Taking this fact into consideration, we hypothesized that CD5 may
modulate the TCR proximal events in the process of Treg cell activation. Thus, we concentrated
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on the receptor proximal signaling events in Treg function and how it is affected by the absence
of the negative regulator CD5. Furthermore, using an in vivo model of DSS-induced colitis,
we show that CD5−/− mice are more resistant to induction of colitis.
Materials and Methods
Mice and cell purification
3 to 4 month old female C57BL/6 wild type or B6-Ly 5.1 mice and age matched CD5−/− mice
in (C57BL/6 × 129) or B6-Ly 5.1 background were used to obtain splenocytes and lymph nodes
(inguinal, axillary, superficial cervical, mandibular and mesenteric). CD4+ T cells were
negatively selected by using mouse CD4 T cell isolation kit (Miltenyi Biotec Inc., Auburn,
CA). Purified CD4+ cells were stained with anti-CD25~FITC (BD Pharmingen, San Diego,
CA) and sorted for CD25− (responder T cells) and CD25+ (Treg cells) fractions using a MoFlo
Cytometer (Dako Cytomation, Fort Collins, CO). Alternatively, the splenocytes and lymph
node cells were separated into the aforesaid two populations by using the mouse CD4+
CD25+ regulatory T cell isolation kit (Miltenyi Biotec Inc., Auburn, CA) according to the
manufacturer’s instructions. The purity of resultant cell populations was assessed by flow
cytometry to be >95%.
In vitro proliferation assay
5 – 6 × 104 CD4+ CD25− wild type responder T cells in RPMI were cultured in a 96-well plate
with equal number of irradiated splenoctyes (2000 rad), 10 µg/ml soluble anti-CD3
(145-2C11), and varying numbers of CD4+ CD25+ Treg cells from wild type or CD5−/− mice.
For Transwell experiments, purified 5 × 105 CD4+ CD25− responder T cells from wild type
spleen and lymph node were incubated with equal number of antigen presenting cells (APC)
as accessory cells and 10 µg/ml anti-CD3 in the presence of 5 or 10 × 105 CD4+ CD25+ Treg
cells from CD5−/− mice in a 24-well plate. 0.4 µm pore size TranswellR (Corning Inc., Corning,
NY) insert was used to separate the Treg cells from responder T cells wherever indicated.
Cultures were incubated at 37°C/5%CO2, pulsed with [3H] thymidine on day 3 for 6 hours,
harvested and read on a β-counter. Proliferation results are presented as mean of counts per
minute (cpm) ± SE of triplicate cultures.
Flow Cytometry and Antibodies
Purified CD4+ CD25+ Treg cells were activated with anti-CD3 for 48 hours and stained with
supernatants from DTA-1 (monoclonal rat IgG2a antibody secreting anti-GITR hybridoma) (a
generous gift of Dr. E. Shevach, NIH) followed by anti-rat Ig~FITC secondary antibody and
analyzed on a FACS Calibur (BD Biosciences, San Jose, CA) (5). Intracellular staining for
Foxp3 expression was performed by following the manufacturer’s protocol (eBioscience, San
Diego, CA) and analyzed on FACS Calibur. Histograms were overlaid using Cell Quest
software (Becton Dickinson, San Jose, CA). Surface staining was performed with anti-
CD4~PE and anti-CD25~FITC antibodies (BD Pharmingen, San Diego, CA) to distinguish
Treg and responder T cell populations.
Calcium release analysis
Intracellular calcium levels were measured by methods described previously (31). Thymocytes
were loaded with 1 µM Indo-1 AM per 10 × 106 cells for 30 min at 37°C. Cells were then
stained with anti-CD8α~PE (53-6.7) and anti-CD25~FITC (7D4) on ice for 30 min along with
5 µg/ml biotinylated anti-CD3 (145-2C11) antibodies, washed and resuspended in insulin and
progesterone free IF-2 + 10% FBS. Anti-CD8 was used to identify CD4+ Treg and T cell
responders by negatively gating for all CD8+ populations, so that the CD4 on Treg is not cross-
linked if a staining antibody to CD4 were to be used. Before analysis, the cells were resuspended
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in pre-warmed media (37°C) and baseline calcium levels were measured for 30 sec. Avidin
(Sigma, St. Louis, MO) was added to the cell suspension and calcium levels were measured
for a total of 5 min. The ratio of fluorescence (405/545 nm) of the gated CD8− CD25−
(responder T cells) and CD8− CD25+ (Treg cells) cells was determined using the MoFlo
cytometer (Dako Cytomation Colorado Inc., Fort Collins, CO) and analyzed using the Summit
software program. An increase in the ratio of violet to blue fluorescence indicates an increase
in the Ca2+ concentration in the cell. Where indicated, biotinylated anti-CD4/L3T4 (RM4-5)
and biotinylated anti-CD28 (37.51) from BD Pharmingen were used as co-stimulants.
Semiquantitative Reverse Transcription PCR
CD5−/− and C57BL/6 mice were sacrificed and 1.5 cm of the descending colon from each
mouse was snap-frozen in liquid nitrogen and subsequently stored at −80°C. Frozen tissues
were homogenized in 1 mL Trizol reagent (Invitrogen, Carlsbad, CA), followed by phenol/
chloroform RNA extraction. RNA was dissolved in nuclease-free water and stored at −80°C
until use. RNA was reverse-transcribed for 1 h at 42°C using oligo-dT primers (Promega,
Madison, WI). cDNA samples were then amplified in a DNA thermal cycler (PerkinElmer
Inc., Boston, MA) using primers specific for GAPDH (sense: 5’-GCT GGA TCC TTC ATT
GAC CTC AAC TAC-3’; antisense: 5’-CGA GAA TTC ATA CCA GGA AAT GAG C-3’),
and Foxp3 (sense: 5’-GGC CCT TCT CCA GGA CAG A-3’; antisense: 5’-GCT GAT CAT
GGC TGG GTT GT-3’). Samples were amplified at subsaturating conditions (28 cycles for
GAPDH and 35 cycles for Foxp3). Cycles for both primers were set at a denaturing temperature
of 95°C (1 min for GAPDH, 30 sec for Foxp3), annealing temperature of 58°C (1 min for
GAPDH, 30 sec for Foxp3), and elongation temperature of 72°C (1 min 30 sec for GAPDH,
40 sec for Foxp3).
Induction of Colitis
Colitis was induced according to the procedure of Murthy et al. (32). 3% Dextran Sulfate
Sodium (DSS – MW 36,000-50,000, MP Biomedicals, LLC, Aurora, OH) was dissolved in
water (w/v) and given to C57BL/6 and CD5−/− mice (4 per group) in place of normal drinking
water. DSS water was provided ad libitum for 7 days; all mice were sacrificed on day 7.
Measurements of the water volume were taken daily to determine the amount of DSS consumed
per mouse. The amount of DSS consumed per mouse was comparable between C57BL/6 and
CD5−/− mice. The DSS induction of colitis in wild type and CD5−/− mice was repeated three
times with similar results.
Clinical Scoring of Colitis
The clinical scoring of a Disease Activity Index (DAI) for DSS induced colitis was based on
weight loss, stool consistency, and bleeding, as previously described (32,33). The DAI was
scored 0–4 for each parameter per mouse and then averaged for each group. Weight loss scores
were determined as 0 = no weight loss, 1 = 1–5% weight loss, 2 = 6–10% weight loss, 3 = 11–
15% weight loss, and 4 = > 15% weight loss. Stool scores were determined as 0 = normal
stools, 2 = loose stools, 4 = diarrhea. Bleeding scores were determined as 0 = no bleeding, 1
= Positive Guaiac occult blood test (minimal color change to green), 2 = Positive Guaiac occult
blood test (maximal color change to blue), 3 = blood visibly present in the stool, no clotting
on the anus, and 4 = gross bleeding from the anus with clotting present.
Tissue Preparation for Histology
After mice are euthanized, the length of the colon was measured and intestine sections were
prepared for histology. Sections were placed in cassettes and stored in 10% buffered formalin
until being embedded in paraffin wax. Cross sections were mounted to slides and stained using
Hematoxylin and Eosin by the University of Kentucky histology services.
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Microscopic scoring of Colon Pathology
Histological scoring was based on the method previously described by Berg et al. and Qualls
et al. (33,34). In brief, colon tissue cross-sections were fixed, embedded in paraffin, and stained
with Hematoxylin and Eosin as described above. Sections were analyzed with a 20X objective.
The colon sections were scored 0–4 based on the level of disease pathology: 0 – No change
from normal tissue, 1 – Mild inflammation present in the mucosa, comprised mainly of
mononuclear cells, with little epithelial damage, 2 – Multifocal inflammation greater than a
grade 1 score including mononuclear cells and a few polymorphonuclear cells (neutrophils),
crypt glands have pulled away from the basement membrane, mucin depletion from goblet
cells, and the epithelium begins to pull away from the mucosa into the lumen, 3 – Mutlifocal
inflammation greater than a grade 2 score including both mononuclear cells and neutrophils
progressing into the submucosa, crypt abscesses present with increased mucin depletion,
presence of epithelial disruption including some ulcers, and 4 – Crypts no longer present, severe
mucosal inflammation mainly composed of neutrophils, and the epithelium was no longer
present. An average of 4 fields of view per colon was evaluated for each mouse. These scores
were averaged per group and recorded as the pathology score ± S.E. All histological interpreters
were blinded.
Statistics
Student t test was employed to determine the statistical significance of differences between
group means.
Results
CD4+ CD25+ Treg cells from CD5−/− mice are more potent in suppressing in vitro proliferation
of CD4+ CD25− responder T cells than Treg cells from wild type mice
It is known that the T cell and B cell receptor proximal signaling can be inhibited by CD5, a
molecule expressed by all T cells. This negative signaling of CD5 occurs via a protein tyrosine
phosphatase, SHP-1 that is recruited to the cytoplasmic domain of CD5 upon T cell activation
(35). We hypothesized that lack of CD5 expression might remove negative effects of CD5 on
TCR signaling and thus enhance Treg function, which is known to be TCR dependent. In order
to test this hypothesis we utilized the CD4+ CD25+ Treg: CD4+ CD25− responder T cell in
vitro co-culture assay system. Treg cells derived from the wild type C57BL/6 mice suppressed
the proliferative response of the CD4+ CD25− responder cells in a dose-dependent manner.
This phenomenon of suppression is also evident when the Treg cells are obtained from
CD5−/− mice. However, the suppression by CD5−/− Treg cells is much more effective than that
observed with the wild type Treg cells at each ratio of the Treg: responder T cell tested (p <
0.05) (Fig. 1A). The increased potency of CD5−/− Treg cells was observed whether the
responder CD4+ CD25− T cells were from C57BL/6 (Fig. 1A) or from CD5−/− mice (Fig. 1B).
The suppression by the wild type Treg cells was slightly less in Fig. 1B than in Fig. 1A,
presumably due to increased proliferation of CD5−/− responder T cells. To be certain that the
difference between BL/6 and CD5−/− mice is not due to strain variations, since CD5−/− mice
were derived from (BL/6 × 129) mixed background, we also compared Treg cells from
CD5−/− mice back crossed to B6-Ly-5.1 mice for 12 generations. First, the suppression by
either wild type or CD5 deficient Treg was statistically significant (p < 0.05 for wild type and
p < 0.001 for the CD5 knockout Treg) in comparison to the T effector proliferation response
in the absence of Treg cells. The Treg cells from the knock-out strain were able to better inhibit
the proliferation of responder T cells (65%) when compared to that seen with the control strain
Treg cells (p < 0.03 when comparing the suppression induced by wild type versus knockout)
(Fig. 1C). This experiment with CD5−/− mice on a BL/6 background further confirms our
finding that lack of CD5 is able to confer an enhanced suppressive property to the naturally
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arising Treg cells. Similar increased potency of CD5−/− Treg cells was observed when they were
isolated from the thymus (data not shown).
Expression of CD4 and CD25 is similar in wild type and CD5−/− mice
To determine if lack of CD5 affects the numbers or phenotype of Treg cells, flow cytometric
analysis of splenocytes, lymph nodes and thymocytes were performed. Fig. 2 shows the number
of cells expressing CD4 and CD25/IL-2 Rα chain and the density of the marker expression on
splenocytes, lymph node cells, and thymocytes from wild type and CD5−/− mice. Lack of CD5
expression on the CD4+ T cells did not affect either the number or density of the marker
expression on the CD4+ CD25+ Treg cells in the CD5−/− mice. Similar results were obtained
with thymocytes. This suggests that CD5 may not have a role in the development of Treg cells
and subsequent maintenance of these cells in the periphery.
Suppressive effects of CD4+ CD25+ Treg cells from CD5−/− mice are cell contact dependent
The suppressive function of CD4+ CD25+ Treg cells may be elicited via secretion of soluble
factor(s) or require Treg-responder cell physical contact. Cell contact has been found to be an
essential requirement for wild type CD4+ CD25+ Treg cells to suppress the in vitro proliferation
of effector T cells. Such a requirement for cell contact has not been shown for in vivo
effectiveness of Treg cells. Treg cells were separated from CD4+ CD25− responder T cells in
culture by inserting a Transwell which allows exchange of macromolecules but not cells. When
Treg cells were incubated along with the responder T cells in the lower compartment, there was
a dramatic reduction (~ 3 fold) in the proliferation which reflects what is seen in a 96 well co-
culture system. However, when the Treg cells were separated from the responder T cells in a
24 well plate with a Transwell insert, proliferative response was significantly increased
compared to the Treg cells in the same compartment (Fig. 3). This indicates that like the wild
type Treg cells, the CD5−/− Treg cells require cell contact with the responder T cells for them
to inhibit the proliferative response. Since some suppression remained even in the transwell
system, it is conceivable that both contact dependent and independent mechanisms may be
involved in suppression.
CD4+ CD25+ Treg mediated suppression of CD4+ CD25− T cell proliferation in CD5−/− mice is
GITR dependent
GITR is known to be expressed by CD4+ CD25+ Treg cells constitutively. GITR is also
inducible on naïve CD4+ T cells activated via the TCR. When engaged by its ligand, GITR-L;
GITR triggers NF-κB activation and prevents in vitro suppression mediated by Treg cells by
enhancing IL-2 secretion by the responder T cells (36). We tested if the increased suppressive
ability of Treg cells is due to increased GITR expression and is GITR dependent. The results
revealed that the cell surface expression of GITR on Treg cells obtained from CD5−/− mice in
resting as well as activated state was similar to that in wild type mice (Fig. 4 and Table I).
Moreover, treatment with DTA-1 (anti-GITR antibody) prevented Treg mediated suppression
of the CD4+ CD25− responder T cell proliferation (data not shown).
Intracellular Foxp3 levels are almost similar in wild type and CD5 knock-out strains
Forkhead/winged-helix protein Foxp3 is critical for the development and function of regulatory
T cells (12,13,37). It is considered as the most specific marker to date to identify CD4+
CD25+ Treg cells. We measured the intracellular protein levels of Foxp3 by flow cytometry in
thymus, spleen and lymph nodes. Although the CD4+ CD25+ Treg cells from CD5−/− mice are
functionally more effective than those from wild type mice in suppressing the proliferation of
CD4+ CD25− responder T cells; intracellular levels of Foxp3 in CD5−/− mice were similar to
wild type strains in primary as well as secondary lymphoid organs (Fig. 5A and Table II show
comparison between CD5−/− mice in BL/6x129 F2 mixed back ground to wild type BL/6 mice;
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Fig. 5B shows comparison between CD5−/− in B6-Ly 5.1 background to B6-Ly 5.1 wild type ).
Since the cells from lymph nodes characterized in Figure 5 were both peripheral (inguinal,
axillary, superficial cervical, mandibular) and mucosal (mesenteric) in origin, we next
measured the expression of Foxp3 in mesenteric lymph node (MLN) cells alone. The %
CD4+ T cells expressing Foxp3 in wild type and CD5−/− MLN were again not different from
each other confirming the findings in Table II and figure 5 (Table III). Therefore, CD5 appears
to affect the function but not the number of Treg cells in the secondary lymphoid organs.
CD4+ CD25+ Treg cells from CD5−/− thymocytes elicit a larger Ca2+ flux than wild type
thymocytes in response to CD3 stimulation
TCR engagement induces release of Ca2+ that is crucial for subsequent intracellular signaling
events leading to activation of transcription factors, cell survival, cell proliferation and cytokine
production. We utilized this principle to test whether the highly potent Treg cells from the
CD5−/− mice have an activated status that is greater than the wild type Treg cells. In order to
determine this, thymocytes from CD5−/− and wild type strains were cross-linked with
biotinylated anti-CD3 antibody and treated with avidin to elicit Ca2+ mobilization. This
generated a tremendous increase in the Ca2+ flux from the CD4+ CD25− T cell population in
wild type as well as CD5−/− thymocytes (data not shown). When gated on the CD4+ CD25+
Treg cells (using CD8 to negatively gate on CD4+ CD8− cells), the magnitude of Ca2+ response
obtained was very modest compared to the responder CD4+ CD25− T cells but was highly
reproducible (Fig. 6A). Interestingly, Ca2+ flux generated by the CD5−/− Treg cells was
consistently elevated in magnitude than that from the wild type Treg cells indicating that the
activation status of CD5−/− Treg cells is higher than the wild type Treg cells. Co-cross-linking
TCR with antibodies to CD3 and co-stimulatory molecules CD4 and CD28 also generated a
better Ca2+ response than with anti-CD3 alone in the Treg cells (Fig. 6B). This Ca2+ flux was
again higher from the CD5−/− Treg cells. Cross-linking CD4 or CD28 by themselves did not
elicit any increased Ca2+ response from the baseline levels (controls not shown). Thus, loss of
CD5 on the Treg cells is enabling these cells to generate stronger signals from TCR than the
wild type Treg cells. The responses with lymph node Treg cells were smaller in magnitude but
showed similar pattern (data not shown). Upon comparison, the suppressive ability of thymus
derived Treg cells from CD5−/− mice were more effective than those from wild type mice (data
not shown) consistent with the findings from the Ca2+ flux data.
Foxp3 mRNA expression is increased in the colon of CD5−/− mice compared to WT
Although the expression of intracellular Foxp3 protein was no different between CD5−/− and
WT lymphoid tissues, it was of interest to determine if there was any difference in the periphery
at the RNA level. Tissues from CD5−/− and WT mice were harvested and processed for mRNA
extraction to be analyzed by reverse transcription PCR. In accordance with the intracellular
flow data, there was no difference in expression of Foxp3 in lymph nodes or in the spleen (data
not shown). However, when analyzing whole colon tissue, there was over a 3 fold increase in
Foxp3 expression from CD5−/− mice compared to WT (Fig. 7). Currently we do not know if
this is due to increased numbers of Treg cells or due to increased expression of Foxp3 per cell
in the colon of the knockout mice.
Dextran Sodium Sulfate (DSS) – induced colitis is less severe in CD5−/− mice compared to
wild type mice
Because it was shown that CD5−/− mice expressed higher levels of Foxp3 in the colon, we
were interested to see if Foxp3 + Treg cells from CD5−/− mice could be more protective than
WT in vivo. To test the effect of loss of CD5, we used an acute colitis model (32). C57BL/6
(WT) or CD5−/− mice were given normal drinking water, or water containing 3% DSS (w/v)
to induce acute colitis over 7 days. Supporting the concept that CD5 inhibits Treg cell function,
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CD5−/− mice were delayed in their development of acute colitis in comparison to WT mice.
Such a delay was observed in three separate experiments. Thus, as shown in Fig. 8A, WT mice
began to show signs of disease activity by day 3, whereas CD5−/− mice showed symptoms of
colitis by day 5 as defined by disease activity index (described in Materials and Methods).
Colon shortening, another indicator of colitis severity, was less in CD5−/− mice (loss of 27%
length) compared to WT mice (loss of 40% length, p < 0.05). Finally, when analyzing the colon
histopathology scores at day 7, CD5−/− mice showed significantly less disease compared to
WT mice (Fig. 8B). Samples of the colon sections are shown in Fig. 8C. There were no
differences in the colon structure between WT and CD5−/− mice that were given water. WT
mice that were administered 3% DSS showed severe inflammation in the mucosa with intense
epithelial disruption and ulceration and almost total loss of the crypt glands and goblet cells.
Colons from CD5−/− colitis mice were much less affected. There was only mild inflammation,
leaving most of the crypts and the epithelium intact.
Although innate cells are critical for colitis development in this model, it is likely that either
cytokines such as IL-10, or TGF-β, and/or or ligands for negative signaling molecules such as
CTLA-4/PD-1 expressed better by CD5−/− Treg cells inhibit innate cell activation accounting
for reduced inflammation. When analyzing the colon for IL-10 and TGF-β mRNA, there was
no difference between CD5−/− and WT mice in either the control or DSS-colitis mice (data not
shown).
Discussion
Treg function is known to be antigen dependent and involves TCR derived signals. Several
previous studies have shown that CD5 can modulate TCR signals. In particular CD5−/−
thymocytes are hyper-responsive to TCR cross-linking (24). In certain models of tolerance
induction increased CD5 expression has been shown to be critical for T cell anergy (28). Also
CD5 expression is modified by the affinity of the antigen - T cell receptor interaction leading
to a model of “sensory adaptation” in which low responsiveness of T cells is associated with
high CD5 density (38,39). If CD5 also affects TCR signaling in Treg cells in a similar manner,
one would predict an increased effectiveness of Treg cells in the absence of CD5, which was
brought out well by the studies presented here. This negative regulatory effect of CD5 on
Treg cell function is consistent with the recent finding that increased cytotoxicity of tumor
infiltrating lymphocytes is correlated with decreased CD5 expression (40).
However, the mechanisms of increased suppression in CD5−/− Treg cells are not yet well
understood. Based on our studies it is unlikely that the increased suppression is due to increased
numbers of Treg cells in CD5−/− mice or due to altered expression of CD4 or CD25 surface
markers. In the in vitro culture system used here, the CD5−/− Treg cells behave like wild type
Treg cells in requiring cell-cell contact for efficient inhibition, suggesting that increased
secretion of inhibitory cytokines is not the major cause of increased suppression in the absence
of CD5. Since GITR expression was linked to delivery of suppressive signals by Treg cells, we
evaluated GITR expression. Although CD5−/− Treg cells required GITR to mediate suppression,
they did not express increased levels of GITR in resting or activated state. Foxp3, the most
Treg specific marker, was expressed at similar levels in Treg cells from several lymphoid organs
in the presence and the absence of CD5.
Despite the well-established need for antigen recognition by TCR in Treg cells, no TCR derived
downstream signaling events have thus far been identified in Treg cells. We are reporting here,
for the first time, that the TCR in Treg cells induces a small but significant calcium flux when
cross-linked alone or together with CD4 and/or CD28. The response is very much less than in
CD4+ CD25− T cells but is highly consistent. This small TCR derived Ca2+ response is
significantly enhanced in the absence of CD5 suggesting that TCR generates better signals in
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Treg cells in the absence of CD5 and thus may contribute to their greater effectiveness. A role
for calcium elevation in Treg function is supported by the finding that NFAT transcription factor
is important for Treg cell function (41). There are reports suggesting that an interaction between
NFAT and Foxp3 is required for the effector function of Treg cells (42–45). Since calcium
signaling leads to activation of NFAT transcription factor, CD5 may be involved in regulating
the activity of Foxp3 via NFAT. Recent studies have identified several Foxp3 interacting
proteins and targets such as NFAT and a cyclic AMP dependent phosphodiesterase among
others which will have to be evaluated in our system as possible targets of CD5 regulation
(46,47).
This increased effectiveness of Treg function is consistent with the recent findings in the model
of experimentally induced allergic encephalitis, wherein CD5 −/− mice were found to be more
resistant to experimental autoimmune encephalitis (EAE) induction (48).
Interestingly, it has been shown that EAE is also more difficult to induce in transgenic mice
that express a CD5 molecule deficient in its interaction with casein kinase 2 (48,49). The
increased resistance to EAE has been interpreted to be due to reduced survival of effector T
cells in these mice. In preliminary studies we observed that anti-DNA antibody production is
reduced in transgenic mice that express DNA specific BCR crossed to CD5 knockout
background. Based on our preliminary results, we propose that the reduced autoimmunity in
the EAE model and in the anti-DNA transgenic mouse model is due to increased effectiveness
of regulatory T cells in the absence of CD5 derived signals. This is supported by several papers
demonstrating the importance of nTreg numbers and function in the regulation of EAE (50,
51).
To test if loss of CD5 affects Treg function in vivo, we evaluated an animal model of colitis in
CD5−/− mice. In vivo, Treg cells can play an important role by regulating inflammatory
disorders. For instance, Treg cells appear to play a role in the prevention of Inflammatory Bowel
Disease (IBD) and experimental murine colitis. Treg cells have been found in human lamina
propria tissue in both inflamed and healthy states (52). In addition, peripheral Treg cells are
significantly lower in number from patients with active ulcerative colitis (UC), a form of IBD,
than those from healthy patients (53). In accordance with this, Treg cells are essential for
prevention and cure of experimental colitis in murine models (54). They are thought to provide
protection at both the site of inflammation and systemically, as Treg cells proliferate in the
lamina propria, spleen, and mesenteric lymph nodes. We utilized an acute model of murine
colitis to monitor the ability of Treg cells to curtail the disease progression for a fixed period
of 1 week. The addition of 3% Dextran Sulfate Sodium (DSS) to drinking water causes a severe
acute colitis during DSS administration. Although it is reported that DSS colitis can be induced
in lymphocyte deficient SCID mice, Kim et al. have shown that lymphocytes are involved in
the onset of DSS colitis by the fact that disease progression was slower in lymphocyte deficient
Rag-1 KO mice compared to the wild type C57BL/6 mice (55–57). Furthermore, a chronic
form of DSS induced colitis has been shown to have a T cell component (58). Hence it is
conceivable that DSS induced colitis is modulated more effectively by CD5 deficient Treg cells.
Our findings in this DSS induced colitis model are in agreement with the in vitro studies which
show that CD5 inhibits Treg function. Specifically, we found that the mice which lack CD5
expression were better able to resist colitis induction when induced by DSS. In each parameter
of disease activity measured, colitis was less severe in CD5−/− mice compared to WT.
CD5−/− mice showed delayed kinetics of disease onset, less colon shortening, and less severe
histopathology compared to WT colitis mice (Fig. 8). This reinforces the idea of CD5 playing
a crucial role in the initial activation of Treg cells in a negative manner. Our observation that
colonic cells from CD5−/− mice express more Foxp3 than those cells from wild type mice may
indicate increased function or number of Treg cells in the colon of CD5−/− mice (Fig. 7).
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Researchers have shown in several colitis models that the Treg mediated suppression of colitis
is due to both IL-10 and TGF-β (16,59). Surprisingly, this suppression may not be due to IL-10
or TGF-β, as mRNA levels were not increased in the colon of CD5−/− mice (data not shown).
The mechanism of colitis suppression in CD5−/− mice is at present unknown. However, our
data are consistent with the concept that Treg cells in CD5−/− mice suppress inflammation more
efficiently than wild type Treg cells. Recently, Uhlig et al. have shown that Foxp3+ CD4+
CD25+ Treg cells are located in the lymphoid tissues of the gut as well as in the lamina propria
under normal and inflamed conditions (60). Since Treg cells are present in the lamina propria
constitutively, the authors suggested a possible role for these cells in intestinal homeostasis
(50). These findings fit with our data; namely that CD5−/− Treg cells may have an increased
ability to control intestinal homeostasis, as the kinetics of colitis onset was increased in WT
mice.
Do other cells such as CD8 T cells and B-1 B cells that express CD5 have a role in the increased
resistance of CD5−/− mice to colitis induction? B-1 B cells appear to suppress colitis since their
absence in the Gαi2 knockout mice makes them susceptible to inflammatory bowel disease
(61). Control of colitis by B cells has been proposed to be due to IL-10 secretion from B-1 cells
(62). Our preliminary studies show that B-1 cell production of IL-10 is not increased in the
absence of CD5 (Sindhava et al unpublished results). In fact some in vitro studies suggest that
CD5 is required for IL-10 production by B-1 cells (63). Hence increased activity of B-1 cells
is not likely the reason for the colitis resistance in the CD5 null mice. Thus far there is no
evidence for CD5 mediated regulation of CD8 T cell function but it cannot be ruled out at this
stage and CD8+ Treg have been shown to regulate colitis (64). It is interesting that a double
knockout for CD5 and the TCRβ molecules resulted in increased chronic colitis compared to
TCRβ KO alone, suggesting in this case, when αβ T cells are absent, the presence of the CD5
molecule helps to suppress colitis (65). The role of CD5 in γδT cells has not yet been studied.
Regardless of the mechanism of DSS-induced colitis suppression in CD5−/− mice, this study
further enunciates the principle that the CD4+ CD25+ Treg cells have the ability to keep colitis
in check and by blocking CD5 (or CD5−/−) the severity of the disease is reduced. Thus
antagonists of CD5 may be useful to ameliorate the severity of inflammatory bowel diseases.
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Figure 1. CD4+ CD25+ Treg cells from CD5−/− mice are more potent than those from wild type
mice in suppressing in vitro proliferation of CD4+ CD25− responder T cells
(A) 6 × 104 CD4+ CD25− cells from C57BL/6 mice were stimulated with 10 µg/ml soluble
anti-CD3 in presence of 6 × 104 accessory cells and varying numbers of CD4+ CD25+ Treg
cells from either 4 month old wild type (C57BL/6) or CD5−/− mice. Results are expressed as
mean ± SE of triplicate cultures. The difference in responses from wild type and knock out
Treg cells was significant (* p < 0.05) at each ratio of Treg: responder T cell tested. Graph is a
representative of one of four independent experiments.
(B) 6 × 104 CD4+ CD25− responder T cells from CD5−/− mice were cultured with CD5−/− APC
(antigen presenting cells) and anti-CD3 in the presence of CD4+ CD25+ Treg cells from either
wild type C57BL/6 or CD5−/− mice. The cpm values obtained after 72 h culture represent mean
± SE of triplicate wells. The graph shown is one of two experiments performed. Some of the
SE bars are too small to be seen. * and # indicate p < 0.05.
(C) 6 × 104 CD4+ CD25− responder T cells from B6.Ly 5.1 mice were cultured with CD5−/−
APC and anti-CD3 in the presence of CD4+ CD25+ Treg cells from either wild type B6-Ly5.1
or B6-Ly5.1.CD5−/− mice. The cpm values obtained after 72 h culture represent mean ± SE of
triplicate wells. The differences in responses with wild type and CD5−/− Treg cells are
statistically significant as indicated.
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Figure 2. Cell surface expression of CD4 and CD25 is similar in wild type and CD5−/− mice
Splenocytes, lymph node cells and thymocytes from 4 month old wild type C57BL/6 or
CD5−/− mice were stained for cell surface expression of CD4 and CD25. The percent positive
spleen cells in viable lymphocyte gate and the mean fluorescence intensity (MFI) (in
parenthesis) are shown within each gated region of the dot plot. This is representative of one
of five independent analyses each involving 3–5 mice.
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Figure 3. CD5−/− Treg cells require cell-cell contact with the responder T cells
5 × 105 CD4+ CD25− responder T cells from C57BL/6 wild type spleen and lymph node cells
were incubated with equal number of APC and 10 µg/ml anti-CD3 in the presence of 10 ×
105 CD4+ CD25+ Treg cells from CD5−/− mice in a 24-well plate. A TranswellR (pore size 0.4
µm) insert was used to separate the Treg cells from responder T cells wherever indicated. Mean
proliferation (± SE) response of triplicate cultures is plotted. The symbols * and # indicate that
the differences between the groups with the same symbols are statistically significant with a
p < 0.001.
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Figure 4. CD5−/− and wild type CD4+ CD25+ Treg cells express similar levels of GITR
5 × 104 sort purified CD4+ CD25+ Treg cells (resting state) and Treg cells treated with soluble
anti-CD3 antibody (6 µg/ml) for 48 hours (activated state) from 3 month old C57BL/6 wild
type or CD5−/− mice were stained with supernatant from DTA-1 hybridoma and anti-rat Ig
~FITC secondary antibody. Flow cytometry analysis shows overlay of the staining from wild
type (‥‥) and CD5−/− mice (—). Results are representative of two independent analyses.
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Figure 5. Intracellular Foxp3 levels in lymphoid organs of CD5−/− mice are similar to those in wild
type strain
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(A) Thymocytes, lymph node cells and splenocytes from 3 month old C57BL/6 wild type and
CD5−/− mice were stained for cell surface expression of CD4 and CD25. The cells were then
permeabilized and stained for intracellular expression of Foxp3. Histograms are overlays of
Foxp3 expression on gated CD4+ CD25+ Treg cells from the lymphoid organs or wild type
(‥‥) and CD5−/− (—) mice. This experiment is representative of three independent analyses.
(B) Lymph node cells and splenocytes from 3–4 month old B6-Ly 5.1 mice (CD5+/+) and age
matched CD5−/− mice in B6-Ly 5.1 background (CD5−/−) were stained as above. Shown is a
dot plot of CD25 and Foxp3 expression indicating the % positive cells ± SE from three mice
in each group.
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Figure 6. CD4+ CD25+ Treg cells from CD5−/− thymocytes elicit a better Ca2+ flux in response to
CD3 stimulation than Treg cells from wild type thymocytes
(A) Thymocytes from either 5 month old wild type (C57BL/6) or CD5−/− mice were loaded
with Indo-1, stained with α-CD8~PE and α-CD25~FITC and treated with 5 µg/ml biotinylated
anti-CD3 as described in Methods. Cells were stimulated with 20 µg/ml avidin at the time
indicated by the arrow. The panel shows changes in the ratio of Indo-1 mean fluorescence
intensity that are indicative of relative Ca2+ concentration in the CD4+CD25+ (gated as
CD8− CD25+ cells) Treg cells. Results represent mean (± SE) of triplicate determinations and
plotted as a function of time (seconds). Graph is representative of two independent experiments.
* indicates p < 0.05 when comparing the responses of wild type and CD5 knockout cells.
(B) Thymocytes from 5–6 month old wild type or CD5−/− mice were loaded with Indo-1 and
stained with fluorochrome conjugated antibodies as in (A) and treated with biotinylated anti-
CD3 (1µg/ml) alone (□) or along with biotinylated anti-CD4 (2 µg/ml) and anti-CD28 (2 µg/
ml) antibodies. Cells were then stimulated with avidin (20 µg/ml) after obtaining a 30 s baseline
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Ca2+ concentration. The change in the ratio of Indo-1 MFI in the Treg cells is plotted as a
function of time (seconds). Results represent mean ± SE of triplicate determinations. * indicates
difference between the responses of wild type and CD5 deficient mice is statistically significant
at p < 0.05. Results are representative of three separate experiments.
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Figure 7. Cells from the colon of CD5−/− mice express higher Foxp3 mRNA than cells from the
colon of WT mice
Colons from CD5−/− or C57BL/6 (WT) mice were homogenized for mRNA extraction. The
mRNA was used for reverse transcription PCR for GAPDH and Foxp3 amplification, which
was subsequently quantified by band density analysis. Data are presented as Foxp3 amplicon
band density relative to GAPDH ± S.E. Data are representative of 3 separate studies. * = p <
0.05 compared to Foxp3 expression from WT colons.
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Figure 8. DSS-induced colitis is less severe in CD5−/− mice compared to WT mice
(A) Groups of 4 mice were administered 3% DSS in drinking water or allowed normal drinking
water for 7 days. The Disease Activity Index (DAI), based on weight loss, stool consistency,
and rectal bleeding, was determined for each mouse. This experiment was repeated two
additional times with similar results. Data are presented as mean DAI ± S.E. * = p < 0.05
compared to DSS treatment alone. Groups: -WT (0% DSS); -WT (3% DSS);  - CD5−/−
(0% DSS);  - CD5−/− (3% DSS).
(B, C) After sacrifice on day 7, colons were removed and tissue sections were prepared for
histology by H & E staining. Histology sections were scored for disease activity ± S.E. Data
are representative of 3 separate studies. * = p < 0.05 compared to DSS treatment alone.
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Table I
Expression of cell surface GITR on Treg cells from wild type and CD5−/− mice
Cell type % GITR+ Resting cells % GITR+ activated cells
WT responder cells 1 ± 0 35 ± 16
WT Treg cells 86 ± 5 48 ± 7
CD5−/− responder cells 1 ± 0 30 ± 20
CD5−/− Treg cells 84 ± 6 44 ± 7
5 × 104 CD4+ CD25+ Treg cells and CD4+ CD25− responder T cells from wild type C57BL/6 and CD5−/− mice were purified by cell sorting. They
were rested or activated with anti-CD3 for 48 h before staining with anti-DTA-1 antibody as described in Methods. Mean ± SE of % GITR positive cells
from three independent experiments is shown. Each experiment involved 3 – 5 mice for isolation of Treg cells. The differences between wild type and
CD5 null mice are not statistically significant (p > 0.05) for both responder cells and Treg cells.
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Table II
Intracellular Foxp3 expression by flow cytometry.
wild type CD5−/−
% Foxp3 +ve Responder cells % Foxp3 +ve Treg cells % Foxp3 +ve Responder cells % Foxp3 +ve Treg cells
Spleen 2 ± 1 26 ± 20 2 ± 1 26 ± 0
Thymus 4 ± 4 16 ± 11 6 ± 6 23 ± 11
Treg cells from spleen and thymus of C57BL/6 (wild type) and CD5−/− were identified by gating on CD4+ CD25+ T cells and Foxp3 expression was
determined by intracellular staining as described in the Methods. Results from two independent analyses are represented as mean ± SD of %CD4+
CD25+ Treg cells staining positive for Foxp3. The differences between wild type and CD5 null mice are not statistically significant (p> 0.05) for both
responder cells and Treg cells.
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Table III
Intracellular Foxp3 expression in mesenteric lymph nodes.
wild type CD5−/−
%CD4+ Foxp3+ MFI %CD4+ Foxp3+ MFI
Spleen 25.5 ± 1.4 384 ± 44 25.8 ± 1.1 400 ± 47
Mesenteric LN 19.25 ± 0.8 345 ± 25 15.8 ± 0.6 322 ± 28
Treg cells from spleen and mesenteric lymph nodes of C57BL/6 (wild type) and CD5−/− mice were identified by gating on CD4+ T cells and Foxp3
expression was determined by intracellular staining as described in the Methods. Results from 4 mice per group are represented as mean ± SE of %
CD4+ T cells staining positive for Foxp3 and mean fluorescence intensity (MFI). The differences between wild type and CD5 null mice are not statistically
significant (p> 0.05) for both responder cells and Treg cells.
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